Pharmaxis Skin Scarring Study Fully Recruited

21st Dec 22

Release Date: 21/12/2022 10:14am

  • Recruitment in the final placebo controlled phase of the study of 42 patients has completed
  • Results expected in Q2 2023 to assess safety profile, improvements in scar appearance and function, and evidence that LOX inhibition is modifying scar tissue at a structural and biochemical level.

Read full media release - pdf

Categories: News and Media